TriSalus Life Sciences, Inc. Cash Flow Statement
TLSI|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
TriSalus Life Sciences, Inc. used $41M in operating cash flow and negative free cash flow of $41M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.11 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$30.0M | -$59.4M | -$47.2M |
| Depreciation & Amortization | $744.0K | $684.0K | $398.0K |
| Operating Cash Flow | -$40.8M | -$50.6M | -$32.3M |
| Capital Expenditures | $345.0K | $588.0K | $655.0K |
| Free Cash Flow | -$41.2M | -$51.2M | -$33.0M |
| FCF Margin | -139.9% | -276.4% | -265.9% |